Announcements
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2024 Health Care Conference
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- argenx to Present at Upcoming Investor Conferences
More ▼
Key statistics
On Monday, argenx SE (ARGX:VIE) closed at 336.30, 10.81% above the 52 week low of 303.50 set on Dec 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 336.30 |
---|---|
High | 336.30 |
Low | 336.30 |
Bid | 332.30 |
Offer | 335.30 |
Previous close | 333.90 |
Average volume | 0.00 |
---|---|
Shares outstanding | 59.43m |
Free float | 59.36m |
P/E (TTM) | -- |
Market cap | 20.30bn EUR |
EPS (TTM) | -5.25 EUR |
Data delayed at least 15 minutes, as of May 20 2024.
More ▼